Strasbourg, France, June 12, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors for unmet needs in neurology, oncology and rare diseases, today announces the appointment of Sylvie Ryckebusch to its board of directors.

 

Sylvie Ryckebusch is a seasoned business development executive who spent twelve years at Merck Serono (Geneva, Switzerland). In her role as head of licensing in neurology and autoimmune disease, she managed a team of business development professionals and was instrumental in numerous product and technology transactions. Most recently, she was appointed chief business officer at the EspeRare Foundation, a non-profit organization which addresses therapeutic unmet needs in rare diseases. Sylvie is also the founder of Octave Biotech Consulting, which advises pharmaceutical and biotech companies on business development strategy and implementation.

 

Sylvie earned a PhD in neurobiology at the California Institute of Technology before completing a postdoctoral fellowship at the Harvard Business School. She worked for four years with McKinsey & Company before joining the pharmaceutical industry.

 

“I am delighted to welcome Sylvie Ryckebusch to Domain’s board of directors,” said Pascal Neuville, CEO of Domain Therapeutics. “Based on her extensive business and strategy experience, she will bring important insights to our licensing strategy and will contribute to the next phase of the company’s growth.”

 

“I am very excited to join the dynamic Domain Therapeutics team,” said Ms. Ryckebusch. “Domain has been able to leverage its unique scientific expertise and technology to deliver promising therapeutics and high-potential collaborations in recent years, establishing the company as a key player in the biotech sector. I look forward to working with the team on future strategic transactions.”

 

About Domain Therapeutics

Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of new drug candidates targeting transmembrane receptors, in particular G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops candidates (allosteric modulators and biased ligands) through its innovative approach and technologies. Domain has three revenue generating pillars to its innovative business model: 1) collaboration with pharma companies for the discovery of new molecules, 2) out-licensing of its bioSens-All™ technology and 3) creation of asset centric vehicles for the development of its internal pipeline of preclinical candidates for central nervous system disorders, cancer and rare diseases. These asset-centric companies attract investment for focused development and exit is through a trade sale at an appropriate inflection point.

www.domaintherapeutics.com